Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16991567 | 0.92 | MEN1 (0.32) | MEN1KMT2AALDH1A1TSHRIDO1 | |
| SCHEMBL20484797 | 0.89 | KMT2A (0.37) | MEN1KMT2AALDH1A1TSHRIDO1 | |
| SCHEMBL21085574 | 0.89 | KMT2A (0.37) | MEN1KMT2AALDH1A1TSHRIDO1 | |
| SCHEMBL25911629 | 0.89 | KMT2A (0.37) | MEN1KMT2AALDH1A1TSHRIDO1 | |
| SCHEMBL1059333 | 0.89 | KMT2A (0.37) | MEN1KMT2AALDH1A1TSHRIDO1 | |
| SCHEMBL25399632 | 0.86 | MEN1 (0.34) | MEN1KMT2AALDH1A1IDO1 | |
| SCHEMBL25399637 | 0.86 | MEN1 (0.34) | MEN1KMT2AALDH1A1IDO1 | |
| SCHEMBL20394069 | 0.84 | BCHE (0.34) | MEN1KMT2ABCHE | |
| SCHEMBL25401583 | 0.82 | — | — | |
| SCHEMBL25401590 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | MEN1 2511/4885KMT2A 1574/4885ALDH1A1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.